acute ischemic stroke
Conditions
Interventions
intervention group:Selective endovascular brain hypothermia combined with edaravone dexborneol
control group:The control group will receive 300?ml 37? saline (30?ml/min) infused into target vessel through a catheter, and then receive edaravone dexborneol (edaravone dexborneol 15 ml +NS 100 ml i
Sponsors
West China hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: (1) age between 18 and 80 years; (2) presenting with symptoms consistent with acute ischaemic stroke; (3) anterior circulation LVO confirmed by CTA, MRA or DSA; (3) <6 h from onset of symptom to groin puncture; (5) the baseline NIHSS score before EVT ranged from 6 to 25; (6) pre-mRS=1; (7) informed consent signed
Exclusion criteria
Exclusion criteria: The exclusion criteria include: (1) intracranial hemorrhage before randomization: including hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc; (2) severe pneumonia or urinary tract infection; (3) allergic to edaravone dextrocamphenol or excipients; (4) a history of congenital or acquired bleeding disorders, coagulation factor deficiency disorders, and thrombocytopenic disorders; (5) systolic blood pressure =180 mmHg or diastolic blood pressure =110 mmHg after antihypertensive treatment; (6) serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 3 times higher than the upper limit of normal; (7) recent or current serum creatinine exceeding 1.5 times the upper limit of the normal range or estimated glomerular filtration rate (eGFR) <60 mL/min; (8) patients who are pregnant or breastfeeding and who plan to become pregnant within 90 days; (9) patients with severe mental disorders or dementia who were unable to cooperate with informed consent and follow-up; (10) Patients with concurrent malignancy or severe systemic disease with an expected survival of less than 90 days; (11) has participated in or is currently participating in another clinical intervention study within 30 days before randomization.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| functional independence;mRS score;SAE; | — |
Secondary
| Measure | Time frame |
|---|---|
| NIHSS score;mortality;Symptomatic intracranial hemorrhage; | — |
Countries
China
Contacts
Public ContactHe Li
West China hospital
Outcome results
None listed